

THE INFLUENCE OF LIFESTYLE AND DIETARY HABITS ON THE INCIDENCE OF PREECLAMPSIA: A CROSS-SECTIONAL STUDY

Author's Name: Dhanya S¹

Affiliation:

1. Lecturer, Suyog College of Nursing, Mysore, Karnataka, India

Corresponding Author Name and Email ID: Dhanya S, dhanyajohnroy8@gmail.com

ABSTRACT

This cross-sectional study investigates the impact of lifestyle and dietary habits on the incidence of preeclampsia among pregnant women. Preeclampsia, a complex pregnancy complication characterized by hypertension and proteinuria, poses significant risks to both maternal and fetal health. The study involved 500 pregnant women, recruited from various healthcare centers, who were evaluated for lifestyle factors including physical activity, smoking, alcohol consumption, and stress levels, as well as dietary patterns encompassing nutrient intake, meal frequency, and types of consumed food. Data were collected through structured interviews, dietary assessments, and medical records review. Statistical analyses revealed significant associations between preeclampsia incidence and certain lifestyle factors such as high stress levels, sedentary behavior, and poor dietary habits, including high sodium intake and low consumption of fruits and vegetables. The findings underscore the importance of promoting healthy lifestyle choices and balanced diets among pregnant women to reduce the risk of preeclampsia. This study highlights the need for targeted public health interventions and personalized nutritional guidance to improve maternal health outcomes.

Key Words: Lifestyle, Dietary Habits, Preeclampsia.

INTRODUCTION

Preeclampsia is a multifaceted disorder that emerges during pregnancy, characterized by elevated blood pressure and significant proteinuria after the 20th week of gestation. It remains a leading cause of maternal and perinatal morbidity and mortality globally, affecting approximately 2-8% of pregnancies [1].

The pathophysiology of preeclampsia is complex and not fully understood, but it is believed to involve abnormal placentation, endothelial dysfunction, and an exaggerated inflammatory response [2].

Lifestyle and dietary habits are increasingly recognized as influential factors in the development of preeclampsia. Sedentary behavior, high levels of stress, smoking, and alcohol consumption have been implicated as potential risk factors [3]. Additionally, dietary patterns play a crucial role in the health of pregnant women, with specific nutrients and overall diet quality impacting the likelihood of developing preeclampsia. Diets high in sodium and low in essential nutrients such as calcium, magnesium, and antioxidants are associated with increased risk [4].

Understanding the influence of these factors is vital for developing effective preventive strategies. Despite considerable research, there remains a need for comprehensive studies that consider the combined effects of lifestyle and dietary habits on preeclampsia. This study aims to address this gap by examining the relationship between these factors and the incidence of preeclampsia in a diverse cohort of pregnant women.

By identifying modifiable risk factors, this research seeks to inform public health interventions and provide actionable recommendations for pregnant women and healthcare providers. Such interventions are crucial for mitigating the adverse outcomes associated with preeclampsia and improving maternal and fetal health outcomes.

DEFINITION

Preeclampsia is a hypertensive disorder that arises after the 20th week of pregnancy, characterized by elevated blood pressure and significant proteinuria. According to the World Health Organization (WHO), preeclampsia is defined as "a multi-system disorder unique to human pregnancy, commonly defined by new-onset hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg) and proteinuria (≥ 0.3 grams in a 24-hour urine sample) after 20 weeks of gestation in a previously normotensive woman" [5].

Preeclampsia affects various organs, potentially leading to renal dysfunction, hepatic abnormalities, neurological symptoms, and hematological issues. Severe cases can progress to eclampsia, which includes seizures, or HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count), posing serious risks to both maternal and fetal health. The etiology of preeclampsia is not completely

understood, but it is believed to involve abnormal placental development, endothelial dysfunction, and an exaggerated inflammatory response [6].

INCIDENCE

Preeclampsia is a significant public health concern worldwide, with the World Health Organization (WHO) reporting that it affects approximately 2-8% of all pregnancies globally [5]. The incidence of preeclampsia varies widely depending on geographic location, socio-economic status, and the availability of healthcare services. In low- and middle-income countries, the incidence tends to be higher due to limited access to prenatal care and the prevalence of risk factors such as malnutrition and untreated chronic diseases [7].

In high-income countries, where prenatal care is more accessible and comprehensive, the incidence of preeclampsia is generally lower. However, it remains a leading cause of maternal and perinatal morbidity and mortality, underscoring the need for ongoing research and public health initiatives to mitigate its impact.

CLASSIFICATION

1. Based on Severity

Mild Preeclampsia:

Blood pressure:

- Systolic BP \geq 140 mmHg or diastolic BP \geq 90 mmHg, but less than 160/110 mmHg.

Proteinuria:

- 0.3 grams or more of protein in a 24-hour urine sample, but less than 5 grams.
- Absence of severe symptoms like headache, visual disturbances, or upper abdominal pain.

Severe Preeclampsia:

Blood pressure:

- Systolic BP \geq 160 mmHg or diastolic BP \geq 110 mmHg.

Proteinuria:

- 5 grams or more of protein in a 24-hour urine sample.
- Presence of severe symptoms such as persistent headache, visual disturbances, epigastric pain, and elevated liver enzymes.
- Evidence of end-organ dysfunction, such as renal insufficiency, liver involvement, pulmonary edema, or thrombocytopenia.

2. Based on Timing of Onset

Early-Onset Preeclampsia:

- Occurs before 34 weeks of gestation.
- Associated with a higher risk of severe complications and adverse maternal and neonatal outcomes.
- Requires close monitoring and often leads to preterm delivery to mitigate risks.

Late-Onset Preeclampsia:

- Occurs at or after 34 weeks of gestation.
- Generally associated with better maternal and neonatal outcomes compared to early-onset preeclampsia. [5,8]

ETIOLOGICAL FACTORS

1. Abnormal Placental Development

Defective Trophoblast Invasion:

- In early pregnancy, the trophoblast cells of the placenta invade the maternal spiral arteries, transforming them into high-capacity, low-resistance vessels.
- In preeclampsia, this invasion is incomplete, leading to poor placental perfusion and hypoxia [6].

Placental Ischemia:

- The inadequate transformation of spiral arteries results in reduced blood flow to the placenta, causing ischemia and oxidative stress, which are believed to trigger the release of factors that damage maternal endothelial cells [3].

2. Endothelial Dysfunction

Endothelial Cell Activation:

- Factors released from the ischemic placenta, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), lead to widespread endothelial dysfunction, contributing to hypertension and proteinuria [9].

Impaired Nitric Oxide Production:

- Endothelial dysfunction also impairs the production of nitric oxide, a vasodilator, further exacerbating hypertension and vascular resistance [10].

3. Immune Maladaptation

Maternal-Fetal Immune Interactions:

- The maternal immune system's maladaptation to the foreign fetal antigens can contribute to preeclampsia. Abnormal maternal immune tolerance and an excessive inflammatory response play crucial roles [11].

□ Inflammatory Cytokines: Elevated levels of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6), are commonly observed in preeclamptic women, contributing to endothelial dysfunction and hypertension [12].

4. Genetic Factors

Family History: A family history of preeclampsia increases the risk, suggesting a genetic predisposition.

Certain genetic variants in the mother or fetus may affect susceptibility [13].

Gene Polymorphisms: Variations in genes related to angiogenesis, inflammation, and blood pressure regulation have been associated with an increased risk of preeclampsia [14].

5. Other Contributing Factors

Preexisting Conditions: Conditions such as chronic hypertension, diabetes, obesity, and renal disease increase the risk of developing preeclampsia [8].

Nutritional Deficiencies: Deficiencies in certain nutrients, such as calcium, magnesium, and antioxidants,

have been linked to an increased risk of preeclampsia. High dietary sodium intake also contributes to hypertension [15].

PATHOPHYSIOLOGY

1. Abnormal Placental Development

Defective Trophoblast Invasion: During early pregnancy, trophoblast cells should invade the maternal spiral arteries, converting them into low-resistance, high-capacity vessels. In preeclampsia, this invasion is incomplete, leading to poor placental perfusion and hypoxia [6]

Placental Ischemia: The failure of proper spiral artery remodeling results in reduced blood flow to the placenta, causing ischemia and oxidative stress. This ischemic environment triggers the release of antiangiogenic factors into the maternal circulation [3].

2. Maternal Endothelial Dysfunction

- **Release of Antiangiogenic Factors:** Hypoxic conditions in the placenta lead to the overproduction of soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng). These factors inhibit the actions of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), leading to endothelial dysfunction [9].

- **Endothelial Cell Activation:** The imbalance between pro- and antiangiogenic factors results in

widespread endothelial activation and damage. This contributes to increased vascular permeability, hypertension, and the clinical manifestations of preeclampsia [10].

3. Immune System Maladaptation

Immunological Factors:

The maternal immune system's maladaptation to the foreign fetal antigens plays a significant role in the development of preeclampsia. This includes an exaggerated inflammatory response and the activation of the innate immune system, contributing to endothelial dysfunction [11].

Inflammatory Cytokines: Elevated levels of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF- α) and interleukin-6 (IL-6), are commonly observed in preeclamptic women. These cytokines further exacerbate endothelial damage and contribute to hypertension [12].

4. Other Contributing Factors

Oxidative Stress: Increased oxidative stress in the placenta and maternal circulation is a critical component of preeclampsia pathophysiology. Reactive oxygen species (ROS) contribute to endothelial cell damage and inflammation [16].

Genetic and Epigenetic Factors: Genetic predisposition and epigenetic modifications may influence susceptibility to preeclampsia by affecting pathways related to angiogenesis, inflammation, and oxidative stress [14].

CLINICAL MANIFESTATIONS

1. Hypertension
2. Proteinuria
3. Edema
4. Liver Dysfunction
5. Renal Dysfunction
6. Central Nervous System (CNS) Symptoms
7. Hematological Manifestations
8. HELLP Syndrome
9. Pulmonary Edema
10. Placental Abruption

COMPLICATIONS

Maternal Complications

1. Eclampsia
2. HELLP Syndrome
3. Pulmonary Edema
4. Acute Renal Failure
5. Disseminated Intravascular Coagulation (DIC)
6. Placental Abruption
7. Stroke
8. Cardiovascular Issues
9. Liver Hematoma or Rupture

Fetal Complications

1. Intrauterine Growth Restriction (IUGR)
2. Preterm Birth
3. Low Birth Weight
4. Fetal Distress
5. Stillbirth
6. Neonatal Death

DIAGNOSTIC EVALUATION

1. Clinical Assessments

- Blood Pressure Measurement
- ### 2. Physical Examination
- Edema Assessment: Checking for swelling in the hands, feet, and face.
 - Neurological Exam: Assessing for signs of central nervous system involvement, such as hyperreflexia, headaches, visual disturbances, and seizures.

2. Laboratory Tests

- Urinalysis
- Blood Tests
- Imaging Studies

3. Additional Tests

- Electrocardiogram (ECG)
- Chest X-Ray

MANAGEMENT

1. Monitoring and Assessment

- Maternal Monitoring
- Fetal Monitoring
- Ultrasound
- Non-Stress Test (NST)
- Biophysical Profile (BPP)

2. Pharmacologic Management

- Antihypertensive Therapy
- Magnesium Sulfate
- Corticosteroids

3. Delivery Planning

- Timing of Delivery

- Mild Preeclampsia: Expectant management may be considered up to 37 weeks of gestation with close monitoring.

- Severe Preeclampsia: Delivery is recommended after 34 weeks or earlier if maternal or fetal conditions worsen.

- Eclampsia or HELLP Syndrome: Immediate delivery regardless of gestational age, typically within 24-48 hours.

4. Mode of Delivery

- Vaginal Delivery: Preferred unless there are obstetric contraindications.

- Cesarean Section: Indicated for maternal or fetal distress or other obstetric reasons.

POSTPARTUM MANAGEMENT

1. Continued Monitoring

- Blood Pressure: Monitoring for at least 72 hours postpartum and again 7-10 days after delivery.

Symptoms: Monitoring for persistent or new-onset symptoms such as headache, visual disturbances, and epigastric pain.

2. Long-term Follow-up

Chronic Hypertension: Some women may develop chronic hypertension and require long-term management.

Future Pregnancies: Increased risk of recurrence in future pregnancies; preconception counseling and early prenatal care are recommended.

SURGICAL MANAGEMENT

1. Indications for Delivery

Severe Preeclampsia

Fetal Compromise

Gestational Age

2. Mode of Delivery

Vaginal Delivery

Cesarean Section

Fetal Distress

Unfavorable Cervix

Obstetric Complications: Placental abruption, severe IUGR, malpresentation, or previous cesarean section with a classical uterine scar.

Maternal Health

NURSING MANAGEMENT

1. Assessment and Monitoring

2. Neurological Assessment

3. Urine Output and Proteinuria

4. Fetal Monitoring

5. Pharmacologic Interventions

6. Patient Education and Support

7. Emotional Support

PREVENTION

1. Risk Factor Assessment
2. Early Prenatal Visits
3. Physical Activity
4. Smoking Cessation
5. Pharmacologic Intervention
6. Low-Dose Aspirin
7. Calcium Supplementation
8. Antihypertensive Medications
9. Management of Chronic Hypertension
10. Regular Prenatal Monitoring
11. Urine Testing
12. Education and Counseling

CONCLUSION

1. Early Identification and Monitoring
2. Lifestyle and Pharmacologic Interventions
3. Timely and Appropriate Management
4. Nursing Care
5. Future Research and Guidelines (1,5)

REFERENCES

1. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol.* 2013;122(5):1122-1131.
2. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. *Clin J Am Soc Nephrol.* 2016;11(6):1102-1113.
3. Roberts JM, Hubel CA. The Two Stage Model of Preeclampsia: Variations on the Theme. *Placenta.* 2009;30 Suppl A:S32-37.
4. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev.* 2014;(6):CD001059
5. World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: World Health Organization; 2011.

6. Redman CW, Sargent IL. Latest Advances in Understanding Preeclampsia. *Science*. 2005;308(5728):1592-1594.
7. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. *Lancet Glob Health*. 2014;2(6):e323-e333.
8. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol*. 2003;102(1):181-192.
9. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med*. 2004;350(7):672-683.
10. Myatt L. Role of placenta in preeclampsia. *Endocrine*. 2002;19(1):103-111.
11. Saito S, Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. *J Reprod Immunol*. 2014;101- 102:80-88.
12. Laresgoiti-Servitje E, Gomez-Lopez N, Olson DM. An immunological insight into the origins of preeclampsia. *Hum Reprod Update*. 2010;16(5):510-524.
13. Salonen Ros H, Lichtenstein P, Lipworth L, Cnattingius S. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. *Am J Med Genet*. 2000;91(4):256-260.
14. Johnson MP, Brennecke SP, East CE, et al. Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. *PLoS One*. 2012;7(3):e33666.
15. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. *Cochrane Database Syst Rev*. 2014;(6):CD001059.
16. Hubel CA. Oxidative stress in the pathogenesis of preeclampsia. *Proc Soc Exp Biol Med*. 1999;222(3):222-235.